Athira Pharma (ATHA) Insider Trading & Ownership $0.38 +0.02 (+6.69%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$0.38 +0.00 (+0.23%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Athira Pharma (NASDAQ:ATHA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage19.80%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$40.24K Get ATHA Insider Trade Alerts Want to know when executives and insiders are buying or selling Athira Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATHA Insider Buying and Selling by Quarter Athira Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/1/2025Mark James LittonCEOSell25,123$0.29$7,285.67 7/1/2025Mark WorthingtonGeneral CounselSell8,526$0.29$2,472.54 7/1/2025Martin Javier SanInsiderSell10,842$0.29$3,144.18 7/1/2025Robert RenningerSVPSell2,897$0.29$840.13 1/2/2025Mark James LittonCEOSell25,107$0.56$14,059.92 1/2/2025Mark WorthingtonGeneral CounselSell8,510$0.56$4,765.60 1/2/2025Martin Javier SanInsiderSell10,826$0.56$6,062.56 1/2/2025Robert RenningerVPSell2,881$0.56$1,613.36 (Data available from 1/1/2013 forward) ATHA Insider Trading Activity - Frequently Asked Questions Who is on Athira Pharma's Insider Roster? The list of insiders at Athira Pharma includes Andrew Gengos, Glenna Mileson, Hans Moebius, James A Johnson, Kelly A Romano, Mark James Litton, Mark Worthington, Martin Javier San, Perceptive Advisors Llc, Rachel Lenington, and Robert Renninger. Learn more on insiders at ATHA. What percentage of Athira Pharma stock is owned by insiders? 19.80% of Athira Pharma stock is owned by insiders. Learn more on ATHA's insider holdings. Which Athira Pharma insiders have been buying company stock? The following insiders have purchased ATHA shares in the last 24 months: Kelly A Romano ($100,208.00), and Perceptive Advisors Llc ($463,476.04). How much insider buying is happening at Athira Pharma? Insiders have purchased a total of 238,488 ATHA shares in the last 24 months for a total of $563,684.04 bought. Which Athira Pharma insiders have been selling company stock? The following insiders have sold ATHA shares in the last 24 months: Andrew Gengos ($4,240.32), Mark James Litton ($38,240.03), Mark Worthington ($14,257.06), Martin Javier San ($9,206.74), Rachel Lenington ($1,439.25), and Robert Renninger ($2,453.49). How much insider selling is happening at Athira Pharma? Insiders have sold a total of 111,981 Athira Pharma shares in the last 24 months for a total of $69,836.89 sold. Athira Pharma Key ExecutivesDr. Mark J. Litton M.B.A. (Age 56)Ph.D., President, CEO & Director Compensation: $882.7kMr. Andrew W. Gengos (Age 60)CFO & Chief Business Officer Compensation: $396.16kMs. Rachel P. Lenington M.B.A. (Age 51)Chief Development Officer & COO Compensation: $578kDr. Kevin Church Ph.D. (Age 39)Chief Scientific Officer Compensation: $123.67kMs. Julie RathbunHead of Investor RelationsMr. Mark F. Worthington J.D. (Age 58)General Counsel & Corporate Secretary Compensation: $503.83k1 recent tradesMs. Samantha WillingChief People OfficerDr. Javier San Martin M.D. (Age 59)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies BTAI Insider Trading CLNN Insider Trading CUE Insider Trading DTIL Insider Trading COEP Insider Trading VTVT Insider Trading KPTI Insider Trading ZIVO Insider Trading RLMD Insider Trading NRXP Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles $100 Million Buyback in Upwork Stock Follows a Strong Quarter Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tCoreWeave and Madrigal's Insider Trades Flash Bullish SignalsPalantir Insider Selling: Risk Signal or Normal Activity?Loop Industries Insiders Buy Stock, Signal Confidence in Outlook This page (NASDAQ:ATHA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
